Ginkgo Bioworks DNA
Valuation
Multiples measured against the stock's own five-year history
Below its usual level · 30th percentile, 5-year average -3.6x
Around its usual level · 50th percentile, 5-year average 2.1x
#2596 of 5329 stocks by PB (1 = cheapest)
Around its usual level · 46th percentile, 5-year average 9.5x
#3881 of 5155 stocks by PS (1 = cheapest)
P/E over five years
Dashed line is the 5-year average; the shaded band is one standard deviation either side.
Morningstar fair value estimate
| Multiple | Current | Forward | 5y average | Percentile vs. own history | Industry rank |
|---|---|---|---|---|---|
| PB | 1.59 | – | 2.14 | 50% (pricier than usual) | #2596 of 5329 (1 = cheapest) |
| PE | -2.30 | -2.64 | -3.65 | 30% (cheaper than usual) | – |
| PS | 4.76 | 6.67 | 9.52 | 46% (cheaper than usual) | #3881 of 5155 (1 = cheapest) |
Percentile is against this stock’s own 5-year valuation range: higher means it’s trading rich relative to its own history, lower means cheap relative to its own history — it is not a comparison against other companies. Forward multiples use consensus estimates for the next twelve months; a forward multiple below the current one usually signals analysts expect earnings to grow.
No comments yet — be the first to weigh in on DNA.
Sign in to join the discussion.